Martin Moser, MD

• Assistant Professor of Medicine
• Department of Cardiology and Angiology
• University of Freiburg
• Freiburg, Germany

In addition quad spasms after squats mefenamic 500 mg otc, however muscle relaxant lorzone mefenamic 500 mg buy with visa, retinal pigment abnormalities can occur independent of skin changes zyprexa spasms mefenamic 500 mg free shipping. Of particular concern are postmarketing reports of macular abnormalities characterized as vitelliform lesions muscle relaxant drugs methocarbamol order mefenamic cheap online, such as those seen in macular degeneration or dystrophy muscle relaxer jokes 500 mg mefenamic buy. Nevertheless, because of the ophthalmologic adverse reactions, regulatory agencies have recommended use of retigabine only in cases where other antiseizure drugs are not adequate or not tolerated. Clinical Uses Tiagabine is indicated for the adjunctive treatment of focal seizures, with or without secondary generalization. In adults, the recommended initial dose is 4 mg/d with weekly increments of 4­8 mg/d to total doses of 16­56 mg/d. Initial dosages can be given twice a day, but a change to three times a day is recommended above 30­32 mg/d. Minor adverse events are dose related and include nervousness, dizziness, tremor, difficulty concentrating, and depression. Pharmacokinetics Absorption of retigabine is not affected by food, and kinetics are linear; drug interactions are minimal. Pharmacokinetics Tiagabine is 90­100% bioavailable, has linear kinetics, and is highly protein bound. The half-life is 5­8 hours and decreases in the presence of enzyme-inducing drugs. The agents described in the previous section are effective for the treatment of focal onset seizures, including focal-to-bilateral tonicclonic seizures (secondarily generalized tonic-clonic seizures), but some can worsen certain seizure types in generalized epilepsy syndromes. In addition, clinical trials of lamotrigine have demonstrated effectiveness in the treatment of generalized tonicclonic seizures (in idiopathic generalized epilepsy) and in the treatment of generalized absence epilepsy. The drug is generally well tolerated; however, it can produce a potentially fatal rash (StevensJohnson syndrome). Although adverse effects are similar to those of other sodium channel-blocking antiseizure drugs, lamotrigine paradoxically may cause insomnia instead of sedation. Lamotrigine causes fewer adverse cognitive effects than carbamazepine or topiramate. It can also improve depression in patients with epilepsy and reduces the risk of relapse in bipolar disorder. Lamotrigine is also approved for primary generalized tonic-clonic seizures and generalized seizures of the Lennox-Gastaut syndrome. Adverse effects include dizziness, headache, diplopia, nausea, insomnia, somnolence, and skin rash. Although the risk of rash may be diminished by introducing the drug slowly, pediatric patients are at greater risk. Pharmacokinetics Lamotrigine is almost completely absorbed and has a volume of distribution of 1­1. The drug has linear kinetics and is metabolized primarily by glucuronidation in the liver to the inactive 2-N-glucuronide, which is excreted in the urine. Lamotrigine is effective in the treatment of focal seizures in adults at dosages typically between 100 and 300 mg/d. The initial dose is 25 mg/d, increasing to 50 mg/d after 2 weeks; thereafter, titration can proceed by 50 mg/d every 1­2 weeks to a usual maintenance dose of 225­375 mg/d (in two divided doses). Therapeutic serum levels have not been established, but toxicity is infrequent with levels < 10 mcg/mL. The combination of lamotrigine and valproate is believed to be particularly efficacious. However, valproate causes a two-fold increase in the half-life of lamotrigine and can increase blood levels correspondingly, leading to a risk of skin rash if valproate is added to a stable regimen of lamotrigine. In patients receiving valproate, the initial dose of lamotrigine must be reduced to 12. Chemistry Lamotrigine was developed when investigators thought that the antifolate effects of certain antiseizure drugs such as phenytoin might contribute to their effectiveness. Several phenyltriazines were developed; although their antifolate properties were weak, some were active in seizure screening tests. The antifolate activity of lamotrigine is not believed to contribute to its therapeutic activity in epilepsy. H2N N Lamotrigine Mechanism of Action the action of lamotrigine on voltage-gated sodium channels is similar to that of carbamazepine. The mechanism by which lamotrigine is effective against absence seizures is not known. Clinical Uses Although most controlled studies have evaluated lamotrigine as add-on therapy, the drug is effective as monotherapy for focal seizures, and lamotrigine is now widely prescribed for this indication because of its excellent tolerability. The drug accesses the luminal side of recycling synaptic vesicles by vesicular endocytosis. Clinical Uses Levetiracetam is effective in the treatment of focal seizures in adults and children, primary generalized tonic-clonic seizures, and the myoclonic seizures of juvenile myoclonic epilepsy. Adverse effects include somnolence, asthenia, ataxia, infection (colds), and dizziness. Less common but more serious are behavioral and mood changes, such as irritability, aggression, agitation, anger, anxiety, apathy, depression, and emotional lability. Brivaracetam exhibits linear pharmacokinetics over a wide dose range (10­600 mg, single oral dose). It is rapidly and completely absorbed after oral administration; has an elimination half-life of 7­8 hours, which allows twice-daily dosing; and has low plasma protein binding (<20%). Coadministration of brivaracetam with carbamazepine may increase exposure to carbamazepine epoxide, the active metabolite of carbamazepine, possibly leading to adverse effects; carbamazepine dose reduction should be considered. Similarly, coadministration of brivaracetam with phenytoin may increase phenytoin levels. Coadministration of other antiseizure drugs is unlikely to affect brivaracetam exposure. Two-thirds of the drug is excreted unchanged in the urine and the remainder as the inactive deaminated metabolite 2-pyrrolidone-N-butyric acid. In generalized convulsive seizures, whether occurring as a secondarily generalized convulsion following a focal seizure or as a primary generalized seizure, excitatory cortical neurons engage subcortical centers, including the thalamus, that relay the excitation throughout both hemispheres. Perampanel is therefore well suited to inhibit this spread of excitation, which may account for its activity in preventing secondary and primary generalized convulsive seizures. Perampanel binds to an allosteric site on the extracellular side of the channel, acting as a wedge to prevent channel opening. Whether it will prove to have the broadspectrum activity of levetiracetam remains to be demonstrated; given the similarity of the mechanisms of action, however, a broad spectrum is expected. Perampanel use is often associated with behavioral adverse reactions including aggression, hostility, irritability, and anger. The frequency of these adverse effects increases in a dosedependent fashion, and they occur more often in younger patients and in those with learning disabilities or dementia. Chemistry Four barbituric acid derivatives were once used for epilepsy: phenobarbital, mephobarbital, metharbital, and primidone. Pharmacokinetics Perampanel has a long half-life, typically ranging from 70 to 110 hours, which permits once-daily dosing. Because of the long half-life, steady state is not achieved for 2­3 weeks; the prescriber should make dosage changes no more frequently than at 2-week (or longer) intervals. Clinical Uses Phenobarbital is useful in the treatment of focal seizures and generalized tonic-clonic seizures. Evidence-based comparisons of phenobarbital with phenytoin and carbamazepine have shown no difference in seizure control, but phenobarbital was more likely to be discontinued due to adverse effects. Phenobarbital may be useful in the treatment of myoclonic seizures, such as in juvenile myoclonic epilepsy, but it is not a drug of first choice. Long-term administration of phenobarbital leads to physical dependence such that seizure threshold is reduced upon withdrawal. The drug must be discontinued gradually over several weeks to avoid the occurrence of severe seizures or status epilepticus. Concomitant use with such agents increases the clearance of perampanel by 50­70%, which may require the use of higher perampanel doses. Perampanel may decrease the effectiveness of levonorgestrel-containing hormonal contraceptives. Doses in the range of 60­200 mg, divided two or three times daily, are typically used. The minimally effective dose may be 60 mg/d, and the median effective dose range may be 100­150 mg/d. The accepted serum concentration reference range is 15 to 40 mcg/mL, although many patients tolerate chronic levels above 40 mcg/mL. Mean steady-state plasma phenobarbital levels with 60 and 100 mg/d dosing are 14 and 21 mcg/mL, respectively. Phenobarbital was introduced into the clinical market in 1912 as a sleeping aid; it was serendipitously found to be useful in the treatment of epilepsy. In comparison with anesthetic barbiturates such as pentobarbital, phenobarbital is preferred in the chronic treatment of epilepsy because it is less sedative at antiseizure doses. Intravenous pentobarbital, however, is frequently used to induce general anesthesia in the treatment of drug-refractory status epilepticus. Phenobarbital is the oldest of the currently available antiseizure drugs; however, the drug is no longer a first choice in the developed world because of its sedative properties and many drug interactions. In the early 1950s, the drug was found to have antiseizure activity in animal models; subsequent evidence showed it to be clinically active in the treatment of epilepsy. It is effective for the treatment of essential tremor and is still used for this indication. Primidone has a larger clearance than most other antiseizure drugs (2 L/kg/d), corresponding to a half-life of 6­8 hours. During chronic therapy, the phenobarbital levels derived from primidone are usually two to three times higher than the primidone levels. Therapeutic Levels & Dosage Primidone is most efficacious when plasma levels are in the range of 8­12 mcg/mL. Concomitant levels of its metabolite, phenobarbital, at steady state, usually vary from 15 to 30 mcg/mL. Primidone should be started at a low daily dose, which is then gradually escalated over several days to a few weeks to avoid prominent sedation and gastrointestinal complaints. Also, in animal models, primidone causes relatively less acute motor impairment than phenobarbital. With chronic treatment, phenobarbital is thought to mediate most of the antiseizure activity of primidone. Attempts to determine the relative contributions of the parent drug and its two metabolites have been conducted in newborn infants, in whom drug-metabolizing enzyme systems are very immature and in whom primidone is only slowly metabolized. In these patients, primidone is effective in controlling seizures, confirming that it has intrinsic antiseizure activity. This conclusion was reinforced by studies in older patients initiating treatment with primidone, in which seizure control was obtained before phenobarbital concentrations reached the therapeutic range. Toxicity the dose-related adverse effects of primidone are similar to those of its metabolite, phenobarbital, except that many patients experience severe adverse effects on initial dosing including drowsiness, dizziness, ataxia, nausea, and vomiting. Tolerance to these adverse effects develops in hours to days and can be minimized by slow titration. However, because the drug can cause both aplastic anemia and severe hepatitis, felbamate is used only for patients with refractory seizures who respond poorly to other medications. Despite the seriousness of the adverse effects, thousands of patients worldwide use this medication. Pharmacokinetics Primidone is completely absorbed, usually reaching peak concentrations about 3 hours after oral administration. The mean terminal halflife of 20 hours in monotherapy decreases to 13­14 hours in the presence of phenytoin or carbamazepine. The dose may be escalated slowly to a maximum dose of 3600 mg/d, although some patients have received doses as high as 6000 mg/d. In addition to its usefulness in focal seizures, felbamate ameliorates atonic seizures as well as other seizure types in the Lennox-Gastaut syndrome. Felbamate decreases the clearance of phenytoin and valproic acid and increases their blood levels; dose reductions of these drugs may be necessary when felbamate is initiated. Felbamate reduces levels of carbamazepine but increases levels of the metabolite carbamazepine epoxide, which may be associated with adverse effects including dizziness, diplopia, or headache. Valproic acid is one of a series of fatty carboxylic acids that have antiseizure activity; this activity appears to be greatest for carbon chain lengths of five to eight atoms. Valproate is especially effective and is considered the first-choice treatment for such patients. However, it has various troublesome side effects and is a known human teratogen; its use is avoided in women of childbearing potential. Other drugs that may have broad activity in generalized epilepsies are topiramate and zonisamide. Mechanism of Action the mechanism or mechanisms whereby valproate exerts its therapeutic actions are not known. Clinical Uses Valproate is one of the most versatile and effective antiseizure drugs. It is widely used for myoclonic (such as in juvenile myoclonic epilepsy), atonic (as in Lennox-Gastaut syndrome), and generalized onset tonic-clonic seizures. Valproate is also effective in the treatment of generalized absence seizures and is often preferred to ethosuximide when the patient has concomitant generalized tonic-clonic seizures. Valproate is also effective in focal seizures, but it may not be as effective as carbamazepine or phenytoin. In addition, it is used as a mood stabilizer in bipolar disorder and as prophylactic treatment for migraine. Valproate was found to have antiseizure properties when used as a solvent in the search for other drugs effective against seizures. Chemistry Valproic acid is a short-chain branched fatty acid that is liquid at room temperature; it is formulated as an oral syrup solution or in gelatin capsules. More commonly, however, the drug is used in a coordination complex-referred to as divalproex sodium-composed of equal parts of valproic acid and the salt sodium valproate.

This causes osmotic extraction of water from cells spasms left shoulder blade generic mefenamic 500 mg line, leading to hyponatremia without a decrease in serum osmolality muscle relaxant dosage discount mefenamic 500 mg line. Acute Renal Failure Acute renal failure has been well described with use of mannitol muscle relaxant brands cheap mefenamic online mastercard. The incidence of acute kidney injury with mannitol use has been estimated to be 6­7% of patients who receive the drug spasms order cheap mefenamic line. Pharmacokinetics the half-lives of conivaptan and demeclocycline are 5­10 hours spasms icd 9 code order mefenamic 250 mg online, while that of tolvaptan is 12­24 hours. Unlike demeclocycline or tolvaptan, conivaptan is administered intravenously and is not suitable for chronic use in outpatients. Other Causes of Elevated Antidiuretic Hormone Antidiuretic hormone is also elevated in response to diminished effective circulating blood volume, as often occurs in heart failure. In patients with heart failure, this approach is often unsuccessful in view of increased thirst and the large number of oral medications being used. In a large multicenter prospective trial, tolvaptan was able to reduce the increase in kidney size and slow progression of kidney failure over a 3-year follow-up period. In this trial, however, the tolvaptan group experienced a 9% incidence of abnormal liver function test results compared with 2% in the placebo group. Conivaptan (currently available only for intravenous use) exhibits activity against both V1a and V2 receptors (see below). The oral agents tolvaptan, lixivaptan, mozavaptan, and satavaptan are selectively active against the V2 receptor. Renal Failure Both lithium and demeclocycline have been reported to cause acute renal failure. Tolvaptan may also cause an elevation in liver function tests and is relatively contraindicated in patients with liver disease. These agents are aquaretics that increase urea and water excretion but not sodium excretion. Urea transport inhibitors have been shown to blunt the increase in urine osmolality seen after desmopressin administration. The combination of loop diuretics and thiazides can therefore reduce Na+ reabsorption, to some extent, from all three segments. Metolazone is the thiazide-like drug usually used in patients refractory to loop agents alone, but it is likely that other thiazides at equipotent doses would be just as effective. The combination of loop diuretics and thiazides can mobilize large amounts of fluid, even in patients who have not responded to single agents. Routine outpatient use is not recommended but may be possible with extreme caution and close follow-up. Clinical experience suggests that in outpatients, adverse effects of thiazides as add-on therapy to loop diuretics can be mitigated by infrequent low-dose therapy. Since these agents have a short half-life (2­6 hours), refractoriness may be due to an excessive interval between doses. It was hoped that continuous loop diuretic infusions would be useful in treating patients with heart failure and diuretic resistance, but one high-quality study did not show a benefit for continuous loop diuretic infusion as opposed to bolus doses. However, after the dosing interval for loop agents is minimized or the dose is maximized, the use of two drugs acting at different nephron sites may exhibit dramatic synergy. Loop agents and thiazides in combination often produce diuresis when neither agent acting alone is even minimally effective. However, excessively rapid diuretic therapy may compromise the effective arterial blood volume and reduce the perfusion of vital organs. Recently, there has been interest in the use of vaptans in heart failure, not only to treat hyponatremia but also to treat volume overload. Electrolyte dysfunction is less likely with a combination of diuretics and vaptans as opposed to higher doses of the diuretics alone. Although some renal disorders cause salt wasting, most cause retention of salt and water. This is because "nonoliguric" forms of acute renal insufficiency have better outcomes than "oliguric" (<400­500 mL/24 h urine output) acute renal failure. Almost all studies done to address this question have shown that diuretic therapy helps in the short-term fluid management of some of these patients with acute renal failure, but that it has no impact on the long-term outcome. The cause of this sodium retention is not precisely known, but it probably involves disordered regulation of the renal microcirculation and tubular function through release of vasoconstrictors, prostaglandins, cytokines, and other mediators. When edema or hypertension develops in these patients, diuretic therapy can be very effective. Certain forms of renal disease, particularly diabetic nephropathy, are frequently associated with development of hyperkalemia at a relatively early stage of renal failure. In these cases, a thiazide or loop diuretic will enhance K+ excretion by increasing delivery of salt to the K+secreting collecting tubule. In these cases, diuretic therapy may be beneficial in controlling the volume-dependent component of hypertension. Reduction of pulmonary vascular congestion with diuretics may actually improve oxygenation and thereby improve myocardial function. Systemic, rather than pulmonary, vascular congestion is the hallmark of this disorder. Diuretic-induced metabolic alkalosis, exacerbated by hypokalemia, is another adverse effect that may further compromise cardiac + function. This complication can be treated with replacement of K and restoration of intravascular volume with saline; however, severe heart failure may preclude the use of saline even in patients who have received excessive diuretic therapy. Hypokalemia can exacerbate underlying cardiac arrhythmias and contribute to digitalis toxicity. Thus, high-dose loop diuretics (up to 500 mg/d of furosemide) or a combination of metolazone (5­10 mg/d) with furosemide (40­80 mg/d) may be useful in treating volume overload in dialysis or predialysis patients. Finally, although excessive use of diuretics can impair renal function in all patients, the consequences are obviously more serious in patients with underlying renal disease. Although hydrochlorothiazide is the most widely used diuretic for hypertension, chlorthalidone may be more effective because of its much longer half-life. Moderate restriction of dietary Na+ intake (60­100 mEq/d) has been shown to potentiate the effects of diuretics in essential hyperten+ + sion and to lessen renal K wasting. There has been debate about whether thiazides should be used as the initial therapy in the treatment of hypertension. This significant result reinforces the importance of thiazide therapy in hypertension. There is also growing evidence showing that spironolactone may be the most effective single agent in the therapy of drug-resistant hypertension, and this effect may extend to dialysis patients. Mechanisms for retention of Na+ by the kidney in this setting include diminished renal perfusion (from systemic vascular alterations), diminished plasma volume (due to ascites formation), and diminished oncotic pressure (hypoalbuminemia). However, cirrhotic patients are often resistant to loop diuretics because of decreased secretion of the drug into the tubular fluid and because of high aldosterone levels. In contrast, cirrhotic edema is unusually responsive to spironolactone and eplerenone. The combination of loop diuretics and an aldosterone receptor antagonist may be useful in some patients. However, considerable caution is necessary in the use of aldosterone antagonists in cirrhotic patients with even mild renal insufficiency because of the potential for causing serious hyperkalemia. It is important to note that, even more than in heart failure, overly aggressive use of diuretics in this setting can be disastrous. Vaptans are relatively contraindicated in patients with liver disease because a study of tolvaptan in treating patients with autosomal dominant polycystic kidney disease resulted in increased transaminases in some patients treated with high-dose tolvaptan. Low-dose tolvaptan, however, may prove to be useful in treating some patients with cirrhosis (those who do not have ongoing liver damage) who suffer from hyponatremia or fluid overload. In these situations, thiazides are also effective but should be used as adjunctive therapy with other measures. Because 2+ loop diuretics reduce Ca reabsorption significantly, they can be quite effective in promoting Ca2+ diuresis. If this occurs, loop diuretics are ineffective (and potentially counterproductive) because Ca2+ reabsorption in the proximal tubule would be enhanced. Thus, saline must be administered simultaneously with loop diuretics if 2+ an effective Ca diuresis is to be maintained. Once the diuresis begins, the rate of saline infusion can be matched with the urine flow rate to avoid volume depletion. Dietary sodium restriction can potentiate the beneficial effects of thiazides on urine volume in this setting. Serum Li+ levels must be carefully monitored in these patients, because diuretics may reduce renal clearance of Li+ and raise plasma Li+ levels into the toxic range (see Chapter 29). Acetazolamide has also shown efficacy in treating polyuria in nephrogenic diabetes insipidus with fewer adverse events. In addition, they may exert an additional benefit in lowering albuminuria in patients with diabetes and microalbuminuria. Their use has been limited in patients with renal dysfunction because of the increased risk of inducing hyperkalemia. Finerenone may afford similar cardiac and renal protection with a lower risk for hyperkalemia. Bokrantz T et al: Thiazide diuretics and fracture-risk among hypertensive patients. Forssmann W-G, Meyer M, Forsmann K: the renal urodilatin system: Clinical implications. Nijenhuis T et al: Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. Shargorodsky M et al: Treatment of hypertension with thiazides: benefit or damage-Effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance. Tovar-Palacio C et al: Ion and diuretic specificity of chimeric proteins between apical Na+-K+-2Cl- and Na+-Cl- cotransporters. The drop in systolic blood pressure and the weight loss are consistent with the rapid diuresis achieved in this patient, with hypovolemia following. This effect has now led to acute kidney injury in this patient with preexisting advanced kidney disease. This case demonstrates the need for very close monitoring of patients after addition of thiazide diuretics to chronic loop diuretic therapy (particularly if they have pre-existing chronic kidney disease). However, compounds that selectively activate certain receptor subtypes or selectively antagonize the actions of these amines are of considerable clinical value. Obesity, a poorly understood condition, appears to involve many receptors, including some histamine and serotonin receptors. It is discussed in a special section following the discussion of serotonin and its antagonists. The ergot alkaloids, compounds with partial agonist activity at serotonin and several other receptors, are discussed at the end of the chapter. Early hypotheses concerning the possible physiologic roles of tissue histamine were based on similarities between the effects of intravenously administered histamine and the symptoms of anaphylactic shock and tissue injury. Histamine plays an important role in gastric acid secretion (see Chapter 62) and functions as a neurotransmitter and neuromodulator (see Chapters 6 and 21). Histamine released by this mechanism is a mediator in immediate (type I) allergic reactions, such as hay fever and acute urticaria. By a negative feedback control mechanism mediated by H2 receptors, histamine appears to modulate its own release and that of other mediators from sensitized mast cells in some tissues. Endogenous histamine has a modulating role in a variety of inflammatory and immune responses. Upon injury to a tissue, released histamine causes local vasodilation and leakage of plasma-containing mediators of acute inflammation (complement, C-reactive protein) and antibodies. This type of release does not require energy and is not associated with mast cell injury or explosive degranulation. Loss of granules from the mast cell also releases histamine, because sodium ions in the extracellular fluid rapidly displace the amine from the complex. Chemical and mechanical mast cell injury causes degranulation and histamine release. Compound 48/80, an experimental drug, selectively releases histamine from tissue mast cells by an exocytotic degranulation process requiring energy and calcium. Histamine is formed by decarboxylation of the amino acid l-histidine, a reaction catalyzed in mammalian tissues by the enzyme histidine decarboxylase. Mast cells are especially rich at sites of potential tissue injury- nose, mouth, and feet; internal body surfaces; and blood vessels, particularly at pressure points and bifurcations. Four different histamine receptors have been characterized and are designated H1­H4; they are described in Table 16­1. For example, clobenpropit, an agonist at H4 receptors, is an antagonist or inverse agonist at H3 receptors (Table 16­1). H4 receptors appear to have very important chemotactic effects on eosinophils and mast cells. They may also modulate production of these cell types and they may mediate, in part, the previously recognized effects of histamine on cytokine production. Tissue and Organ System Effects of Histamine Histamine exerts powerful effects on smooth and cardiac muscle, on certain endothelial and nerve cells, on the secretory cells of the stomach, and on inflammatory cells. This H1-mediated effect is an important component of the urticarial response and reactions to insect and nettle stings. The blood pressure changes are caused by the vasodilator action of histamine on arterioles and precapillary sphincters; the increase in heart rate involves both stimulatory actions of histamine on the heart and a reflex tachycardia. Flushing, a sense of warmth, and headache may also occur during histamine administration, consistent with the vasodilation. In humans, the cardiovascular effects of small doses of histamine can usually be antagonized by H1-receptor antagonists alone. Direct cardiac effects of histamine include both increased contractility and increased pacemaker rate. In the guinea pig, this effect is the cause of death from histamine toxicity, but in humans with normal airways, bronchoconstriction following small doses of histamine is not marked. Although methacholine provocation is more commonly used, tests using small doses of inhaled histamine have been used in the diagnosis of bronchial hyperreactivity in patients with suspected asthma or cystic fibrosis.

The cutaneous lesions of disseminated coccidioidomycosis are usually asymptomatic muscle relaxant natural remedies mefenamic 500 mg purchase free shipping, and typically begin as papules that evolve to pustules muscle relaxant injection for back pain 250 mg mefenamic buy with visa, plaques spasms near heart discount 500 mg mefenamic with visa, or nodules with minimal surrounding erythema spasms hindi meaning order mefenamic mastercard. In time quinine muscle relaxant mechanism purchase mefenamic 500 mg amex, lesions may enlarge and become confluent with the formation of abscesses, multiple draining sinus tracts, ulcers, cellulitis, verrucous plaques, and granulomatous nodules. Endemic areas include the river valleys of the Midwestern and Southeastern United States, Southeastern South America, and Southern and East Africa. The skin findings associated with disseminated histoplasmosis may consist of lesions of multiple morphologies, including erythematous papules, necrotic umbilicated papules and nodules mimicking molluscum, folliculitis, acneiform eruptions, rosacea-like eruptions, psoriasiform eruptions, ulcers, vegetative plaques, and pyoderma gangrenosum-like lesions. The oral mucosa may also be affected, and nodules and ulcerations of the soft palate, oropharynx, epiglottis, and nasal vestibule are sometimes seen. Therapy with voriconazole has been reported to be associated with improved survival and fewer side effects, compared to amphotericin B. Skin lesions are present in about 70% of patients, and typically consist of umbilicated papules favoring the face, pinnae, upper trunk, and arms. Atypical lesions are also common, and may resemble folliculitis, abscesses, warts, furuncles, and cutaneous horns. Electrofulguration with repeated curettage is effective for multiple large and confluent lesions. For cases refractory to standard therapies, imiquimod 5% cream may be effective in both children and adults. Crusted scabies commonly presents with extensive thick hyperkeratotic plaques with dirty gray brown scale, involving atypical locations such as the scalp, beard area, palms, and soles. While an immunocompetent host is estimated to harbor 10­15 mites, a gram of crust from an individual with crusted scabies may harbor thousands of mites. For classic scabies, a topical scabicide or oral ivermectin (200 g/kg weekly) ×2 doses is usually effective. Saiag P et al: Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. Rosenthal D et al: Human immunodeficiency virusassociated eosinophilic folliculitis. A unique dermatosis associated with advanced human immunodeficiency virus infection. Transmission is predominantly via tick bites, with certain pathogens transmitted by human body lice and mites. Fever, headache, myalgia, and malaise are common to rickettsial, ehrlichial, and Anaplasma infections; rash is common in rickettsial disease, occasional in ehrlichial infection, and rare in anaplasmosis. The early signs and symptoms of infection are often nonspecific and can mimic self-limited viral illnesses or other life-threatening illnesses. Early empiric treatment with doxycycline should be considered in highly suspicious cases until rickettsial infection is definitively ruled out, as delayed treatment can lead to severe sequelae and high mortality rates. Early nonspecific symptoms can mimick benign viral illnesses and should be considered in any patient who presents with constitutional symptoms, fever, headache, and a characteristic petechial rash. The advent of modern molecular technologies, including genetic analysis, has allowed for significant taxonomic reclassification of the rickettsiae including moving the family Bartonella (see Chapter 192) and the genus Coxiella out of the order Rickettsiales to the orders Rhizobiales and Legionellales, respectively. Several non-rickettsial agents that were historically included in the group of infections loosely termed the rickettsioses remain incorporated in the discussion of rickettsial disease herein to reflect that precedent. Rickettsiae are propagated by arthropod vectors that use mammals (and sometimes the arthropods themselves) as reservoirs of infection. Rickettsiae are separated into the spotted fever group and the typhus group on the basis of common genetics, immunologic patterns, and intracellular growth characteristics. The typhus group lives entirely within the cell cytoplasm, whereas the spotted fever group can reside within the cytoplasm or nucleus. Rickettsiae are differentiated by unique antigenic structures on cell surface proteins. Rickettsia rickettsii has two major surface proteins, outer membrane protein A (OmpA) and B (OmpB), which are the main targets for serological testing. Infection occurs through arthropod-induced breaks in the skin allowing access of the pathogen to the blood and lymph. Spotted fever rickettsiae are injected into the host through the saliva of the feeding tick, whereas typhus group rickettsiae enter through the feces of infected human body lice or fleas. Manipulation of the bite site, a long attachment of the arthropod, and exposure to arthropod hemolymph during tick removal aid in the transmission of pathogenic organisms. The rickettsial organisms then spread via the hematogenous and lymphatic systems, attach to endothelial cell membranes, and are phagocytosed. Spotted fever group rickettsiae stimulate host cells to produce reactive oxygen species and cause actin polymerization that aid in bacterial extrusion. In contrast, typhus group rickettsiae replicate intracellularly until the host cell bursts. Fatal outcomes have been reported in 5% of treated cases, and as high as 20% of untreated cases. First Line Treatment Adultsb: Doxycycline 100 mg po q12h × 5­10 days Childrenc: Doxycyline 2. Adults: Doxycycline 200 mg po q12h × 1 day or 100 mg po q12h for 2­5 days Childrenc: Doxycyline 2. Self-limiting Endemic typhus (Rickettsia typhi; Rickettsia felis) Xenopsylla cheopis (rat flea), Ctenocephalides felis (cat flea) Southeast United States, Gulf region, Southern California; worldwide most cases in Africa (reported on all continents except Antarctica) Summer 1­2 weeks (12 days) Excellent prognosis with treatment. Complicated disease occurs with alcoholism, elderly, hematologic disorders, and exposure to sulfacontaining drugs. Recovery of strength in 2­3 months Adultse: Doxycycline 200 mg single dose (or until afebrile for 24 h) Childrenc: Doxycyline 2. One or two classic symptoms, outlined in Table 199-2, may be seen at presentation, but only about 60% of patients will have the complete clinical triad of fever [>39. Fever usually presents within the first 3 days of the illness, followed by a characteristic rash 2­4 days after the onset of fever. The rash usually starts on the wrists and ankles, spreading centripetally over the next 6­18 hours. Atypical "spotless" fever, seen in approximately 20% of cases does not imply milder disease, and is more common in the elderly and darker-skinned individuals. Necrosis from overwhelming vasculitis is rare and preferentially occurs in peripheral locations such as the digits, penis, and scrotum. Periorbital edema, abdominal pain mimicking appendicitis (children >adults), conjunctival injection, palatal petechiae, edema of dorsal hands, calf pain. Erythematous blanching macules and/or papules 2­4 days after fever onset; starts at wrists/ankles and spreads centripetally; may involve palms, soles. Variably elevated: Liver transaminases, lactate dehydrogenase, creatine kinase, bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine. Cerebrospinal fluid: Leukocytosis, moderately elevated protein, and a normal glucose level. Cardiovascular: Hypotension, hypovolemia, peripheral edema, inappropriate tachycardia, myocarditis, arrhythmias. Gastrointestinal: Bleeding, perforation, hepatomegaly, jaundice Neurologic: Confusion, delirium, stupor, meningismus, coma, motor deficits, cranial nerve palsy, deafness, photophobia, hallucinations, seizures, GuillainBarré syndrome. Fever, chills, headache, malaise, myalgia, nausea, vomiting, anorexia, photophobia. Abdominal pain mimicking appendicitis (children >adults), conjunctival injection, palatal petechiae, edema of dorsal hands, calf pain. Rash Rare Common laboratory abnormalities Leukopenia, lymphopenia, thrombocytopenia, transaminitis, and anemia Thrombocytopenia, transaminitis, leukopenia, anemia, elevated creatinine. Systemic sequelae Respiratory: Cough, dyspnea, respiratory insufficiency/ adult respiratory distress syndrome. Neurologic: Meningoencephalitis, altered mental status, cranial or peripheral motor nerve paralysis, sudden transient deafness. Other: Acute renal failure, disseminated intravascular coagulation, and pericarditis. General: Septic or toxic­shocklike syndrome (see Chapter 177), coagulopathy, disseminated intravascular coagulation (see Chapter 144), rhabdomyolysis, pancreatitis. Neurologic: Brachial plexopathy, demyelinating polyneuropathy, cranial nerve paralysis. Other: Acute abdominal syndrome, myocarditis, acute renal failure, hemorrhage, opportunistic infections. Truncal and facial hemorrhagic macules and papules 7 days after the onset of the rash. Erythematous macular lesions on the palm may develop into a petechial rash that spreads centrally. Petechial lesions on the arm of a child with fulminant Rocky Mountain spotted fever. The white blood cell count is typically normal, however an increase in bands may be observed. Early lesions demonstrate dermal edema with a predominantly perivascular lymphohistiocytic infiltrate and extravasated erythrocytes. Basal cell vacuolization, lymphocytic exocytosis, fibrin thrombi, and capillary wall necrosis can also be appreciated. Tetracyclines, specifically doxycycline, are the drugs of choice for all rickettsial diseases in patients of all ages, even during pregnancy. Although repeated exposure to tetracycline increases the risk of tooth staining, studies suggest that limited use of this antibiotic in children during the first 6­7 years of life has a negligible effect on the color of permanent incisors. It detects convalescent antibodies (at a diagnostic titer of 64 IgG and 32 IgM) but is seldom diagnostic before the seventh day of disease, and often not until far into the second week. Because of inferior sensitivity and specificity, the Weil­Felix test (agglutination of certain Proteus sp. Vascular lesion of Rocky Mountain spotted fever as seen in an arteriole in the skin. The classic cutaneous hallmark of this group is the tache noir, occurring in about 13%­68% of patients with R. Side effects include aplastic anemia, reversible bone marrow suppression, and gray baby syndrome in near-term gravidae,12 Aggressive supportive care is crucial, with particular attention to electrolyte and fluid balance. May cause petechial rash in children who appear well "Slapped cheek" appearing erythematous rash on face, lacy erythematous rash on trunk. Clinical history, symptoms, physical exam, and laboratory findings should guide approach to management and treatment. Clinicians may consider a "watch-and-wait" approach for 24­48 h for patients early in the course of illness who have nonsupporting history, nonspecific clinical signs, and normal lab findings. Doxycycline is the drug of choice for the treatment of presumptive or confirmed rickettsial disease in both adults and children. Tetracyclines are typically contraindicated in pregnancy but may be warranted in life-threatening cases of Rocky Mountain spotted fever when clinical suspicion arises. When early invasive meningococcal infection cannot be ruled out, antibiotics for Neisseria meningitides must be started. Prophylactic use of antibiotics after a tick bite is not recommended, as atypical presentations may result, delaying adequate diagnosis and treatment. In patients for whom tetracyclines are absolutely contraindicated, chloramphenicol can be used for rickettsial disease; rifampin or rifabutin may be considered for the ehrlichioses/anaplasmosis. When treating ehrlichial infections, consider continuation for 14­21 days to allow for adequate treatment of concomitant Lyme disease in areas endemic for Borrelia burgdorferi. Macrolide antibiotics may offer a better risk/benefit ratio than tetracyclines in the pediatric age group, however, doxycycline is still first-line therapy. Rickettsialpox is an acute, self-limited, febrile disease so named because of its clinical resemblance to varicella (chickenpox). Mus musculus, the house mouse, is the reservoir, and the vector is the rodent mite, Liponyssoides sanguineus (formerly Allodermanyssus sanguineus). Most cases of rickettsialpox in the United States have occurred in large metropolitan areas of the Northeastern United States, with approximately one-half of the cases reported from New York City alone. A primary lesion occurs at the site of the mite bite as early as 1­2 days after transmission. Vesicle formation is followed by desiccation which produces an eschar to form the characteristic tache noir. Approximately 7 days after the primary lesion appears, fever, chills, diaphoresis, myalgia (often manifesting as backache), malaise, and headache begin. Two to three days after the onset of systemic symptoms, a generalized papulovesicular eruption occurs. Less frequently, an enanthem, photophobia, generalized lymphadenopathy, and gastrointestinal symptoms may be noted. Thrombocytopenia is common during the acute febrile illness, and a mild leukopenia with a relative lymphocytosis may be seen. Primary lesions are characterized by extensive necrosis and an acute inflammatory infiltrate. Secondary papulovesicular lesions display a subepidermal split with superficial edema, and a perivascular lymphohistiocytic infiltrate that can become vasculitic. Antibody titers peak after 3­4 weeks and could be delayed for up to 8 weeks with antibiotic use. If a tache noir is seen, one must also consider brown recluse spider bite, cutaneous anthrax, scrub typhus, rickettsialpox, aspergillosis, or mucormycosis. A crusted, ulcerated lesion with eschar and a faint red halo at the site of the mite bite. Mediterranean spotted fever, 32-year-old Caucasian male with eschar on thigh, followed by fever, and erythematous papules and small pustules. In varicella, one observes a "dewdrop on a rose petal," referring to a primarily vesicular lesion surrounded by macular erythema.

Production involves the sterile growth of cell lines that host the vaccinia virus spasms from coughing generic mefenamic 500 mg with amex. By increasing purity and reducing contamination spasms foot order discount mefenamic on line, these vaccines may help avoid the allergic and autoimmune reactions thought to stem from the nonvaccinia material in calf-lymph vaccines muscle relaxant high blood pressure discount 250 mg mefenamic. These reactions include hypersensitivity reactions muscle relaxant remedies buy generic mefenamic 500 mg line, erythema multiforme spasms right arm purchase 500 mg mefenamic with mastercard, and possibly the encephalitic and cardiac reactions. But because they are live viruses similar in immunogenicity to Dryvax, their safety profiles are not significantly different with regard to adverse events specifically associated with vaccinia exposure. Another strategy is the development of vaccines using strains of vaccinia attenuated by serial passage through nonhuman tissue. This leads to a reduced capacity for replication and potentially reduced adverse effects. The modified vaccinia Ankara strain is produced by passage through chick embryo fibroblasts. No significant complications were reported with its use in Germany and Turkey in the 1970s to help people at high risk for side effects (such as those with atopic dermatitis/eczema, etc. Studies in Japan in the 1960s and 1970s found it to have less local and systemic reactogenicity but similar protective immunity to conventional smallpox vaccines. Further clinical study of the modified vaccinia Ankarabased and Lc16m8 vaccines is under way. It was first identified in 1958 as an illness of cynomolgus monkeys, hence its name. Monkeypox was first documented to cause human illness in 1970 in Zaire (the present Democratic Republic of the Congo), when an illness similar to smallpox was noted after eradication of the latter. It is endemic in the rain forest countries of Central and West Africa, occurring in sporadic outbreaks. Despite its recent recognition, monkeypox has presumably caused illness for thousands of years. Person-to-person spread via respiratory droplets and close contact can occur as with smallpox, but usually in a more limited manner. Outbreaks in the Democratic Republic of the Congo in 1996­1997 showed sustained human-to-human transmission for the first time. This may reflect decreased immunity secondary to the discontinuation of routine smallpox vaccination. All cases are thought to be associated with contact with ill pet prairie dogs previously housed with African rodents imported from Ghana. Like variola and vaccinia viruses, it is also of the genus Orthopoxvirus and has an oval or brick shape on electron microscopy. The monkeypox viral genome is 96% identical to that of the variola virus at the central region, which encodes essential enzymes and structural proteins. The end regions that encode virulence and host-range factors are substantially different, and the range of hosts for the monkeypox virus is much wider than that for variola virus. The natural reservoir is unknown but is thought to be wild rodents such as the squirrel. The virus multiplies locally at the site of injury; then it is rapidly transported to regional lymph nodes, where multiplication continues. The monkeypox virus is also transmissible from person-to-person via aerosolization of the virus or contact with lesions or body fluids during the first week of the rash, although this transmissibility is significantly lower than that for smallpox. This likely reflects the fact that West African strains of monkeypox virus are less virulent than those of Central Africa. Significant lymphadenopathy develops 1­2 days before the onset of the rash, usually in submandibular, cervical, or inguinal areas. A prodrome of fever, chills, malaise, headache, myalgias, and back pain occurs, lasting 2­3 days. Most commonly, the eruption begins on the face and/or trunk, with the lesions spreading in a centrifugal pattern to become generalized. In the outbreak in the United States, only one patient (a child) had a generalized rash as extensive as that seen in cases in Africa. The other affected individuals had only localized lesions, mostly on the hands, associated with direct contact with the infected animals Cutaneous Lesions. Orf and bovine stomatitis, caused by poxviruses of family Parapoxviridae, can produce similar skin lesions but these are localized. Also in the differential diagnosis are drug eruptions, eczema herpeticum, and rickettsialpox (see Box 195-1). Affected individuals may also develop pneumonitis (12%), encephalitis (fewer than 1%), and ocular complications, including scarring with corneal lesions. Death is generally in the second week of disease and is secondary to bacterial superinfection, gastrointestinal complications, or pulmonary complications. These are likely compounded by poor nutrition and inaccessibility of medical care. Cidofovir may be considered in severe cases, but there is no available data on its clinical efficacy in humans. Global eradication of monkeypox is more difficult than smallpox eradication, because the wide range of hosts for monkeypox virus allows it to maintain an animal reservoir while sporadically causing human disease. Vaccination with the calflymph-derived smallpox vaccines (vaccinia virus) was found to be effective in preventing human monkeypox. Observation of cases in Africa showed 85% protection against monkeypox; cases that do occur are milder and even subclinical when they occur in vaccinated individuals. Leukocytosis, elevated transaminase levels, and low blood urea nitrogen levels are often seen. On examination of skin biopsy specimens, the features are indistinguishable from those of smallpox. There is similar dermal papillary edema, acute inflammation, and ballooning degeneration of keratinocytes. Electron microscopy of material from scabs or fluid from skin lesions can be used to determine the presence of an orthopoxvirus, but it cannot distinguish among them. Assays for specific antibodies against monkeypox can differentiate it from other poxviruses. The features of monkeypox are clinically similar to but less severe than those of ordinary smallpox (variola major). Lymphadenopathy is a distinctive hallmark of monkeypox not usually seen in smallpox. It is an occupational disease of milkers, veterinarians, and workers in the meat industry. No natural cases of human-to-human transmission have been reported, only experimentally transmitted cases in the laboratory setting. The virus typically is found at the teats and mouth of cattle but may also occur on the trunk and legs. Humans are accidental hosts following contact with infected animals or contaminated fresh meat. Paravaccinia virus is transferred by direct inoculation into the skin, often through a break in the skin barrier. In a minority of cases, the infected individual develops mild systemic symptoms such as a transient low-grade fever. The sites of inoculation of paravaccinia virus are usually the hands and, on occasion, the face. They can then form papulovesicles with a target-like appearance-a red center surrounded by a white or gray ring and outer red halo. Early lesions show vacuolization and ballooning of cells in the upper third of the epidermis, which sometimes leads to multilocular vesicles. Multiple lesions at the site of a second-degree scalding burn sustained in a milking barn. Neutrophils are seen in the epidermis and superficial papillary dermis with epidermal necrosis. Mature lesions have finger-like epidermal projections, papillary dermal edema, and a mixed inflammatory infiltrate that includes lymphocytes, histiocytes, and eosinophils. There is no cross-immunity between orthopoxviruses and parapoxviruses, and thus smallpox vaccination (vaccinia virus) has no effect on this illness. Prevention mainly consists of isolation of infected animals and contact precautions. Electron microscopy of blister fluid or crusts can identify the characteristic cylindrical shape of parapoxviruses. It has a longer incubation period, causes more pain and lymphadenopathy, and has led to death in persons with immunocompromise or atopic dermatitis. It is an endemic disease in sheep and goats that usually affects the area around the lips and nostrils of the animal, as well as the teats of ewes suckling young. It is transmitted to humans through contact with infected tissue or fomites, and human infections have been noted after vaccination of sheep herds. Vaccination of animals with unattenuated virus leads to milder disease in the animal, but can result in infection of humans exposed to the vaccinated animal. Orf virus is the prototypic species of the genetically heterogeneous Parapoxvirus genus. Electron microscopic analysis can distinguish this Parapoxvirus from Orthopoxviruses such as variola (smallpox). Human disease is more commonly seen in farmers and shepherds, but anyone who has contact with small ruminants is at risk. Although sheep and goats are the more common sources of infection, the virus has also been found in camels, mountain goats, gazelles, and musk oxen. Disease can occur after contact with animals or fomites such as barn doors, feeding troughs, wire fencing, and bottles. The lesions then evolves into a targetoid nodule with a red center, white ring, and peripheral rim of erythema. Systemic findings are uncommon in immunocompetent individuals but can include lymphadenopathy and lymphangitis. Clinical Manifestation of Orf Clinical Manifestations One to four papules on hand (typically only one lesion): begin as a red maculopapular lesion Vesicle Target lesion, with red center, white middle ring, and red halo Acute weeping stage Regenerative dry stage with black dots Papillomatous stage Regressive stage with dry crust and eventual shedding of the scab Typically no scarring occurs. Laboratory Analysis Can confirm by histology, viral culture, increase in serologic titers, or complement fixation. Electron microscopy of lesional skin shows brick-shaped viral particles (200­ 380 nm in length); intranuclear inclusions are occasionally seen. Other Notes Systemic symptoms are rare, but may include lymphadenopathy and lymphangitis, fever, rigors, drenching sweat, malaise, and urticaria. Immunocompromised individuals can develop progressive destructive lesions that may require interventions such as débridement or antiviral therapy such as cidofovir cream. Supportive care is the most appropriate intervention for immunocompetent patients. Application of compresses, culture of lesion specimens, and antibiotic coverage may be appropriate if secondary bacterial infection is suspected. Immunocompromised patients may require medical intervention (see Section "Prognosis and Clinical Course"). Patients with an impaired skin barrier from either abrasions or intrinsic skin disease. It is characterized by smooth, dome-shaped, discrete, opalescent papules with a central core that occasionally develops surrounding areas of scale and erythema (molluscum dermatitis). Patients and families are bothered by this infection because of its often prolonged course, as it may persist for months to years. Sexually transmitted disease occurs in adults but is extremely unlikely in children. Electron microscopy may be helpful in distinguishing between parapoxviruses and other types of poxviruses but is not diagnostic for orf; similar limitations exist with serologic testing. A variety of bacterial and infectious diseases can present with findings similar to those of orf (see Box 195-4). Sporotrichosis begins as a single necrotic nodule but is followed by multiple nodules arising in a linear fashion along the lymphatics. Primary innoculation tuberculosis and atypical mycobacterial infection can give rise to ulcerative lesions that may take months to years to heal. Discrete, solid, skin-colored papules, 1­2 mm in diameter with central umbilication. Bath towels, swimming pools, and Turkish baths have all been reported as sources of infection, and individuals involved in close contact sports. Recent reports also document the possibility of vertical transmission from mother to neonate during the intrapartum period. Most patients develop multiple papules, often in intertriginous sites, such as the axillae, popliteal fossae, and groin. Genital and perianal lesions can develop in children and are only rarely associated with sexual transmission in this population. The latter often results from koebnerization or development of lesions at sites of trauma. Erythema and eczematous changes may occur around lesions; this is termed molluscum dermatitis. Patients with acquired immunodeficiency syndrome may develop large and extensive lesions involving both genital and extragenital sites. It shares a number of genomic similarities with other poxviruses, and approximately two-thirds of the viral genes are similar to those of vaccinia and variola virus. Virus replicates within the cytoplasm of epithelial cells, and infected cells replicate at twice the baseline rate. Histopathology (skin biopsy, H&E) shows downgrowth of infected epidermal cells bearing large eosinophilic cytoplasmic inclusion bodies (Henderson-Paterson bodies).

Mefenamic 250 mg free shipping. Heart Failure | Antihypertensives (Calcium Channel Blockers) CCB's.

References

• Antman EM, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
• Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372: 1073-1087.
• Xu PX, Adams J, Peters H, et al: Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia, Nat Genet 23(1):113-117, 1999.
• Fukunaga K, Shioda N. Pathophysiological relevance of forkhead transcription factors in brain ischemia. Adv Exp Med Biol 2009;665:130-42.
• Lees OH. Th e surgery of endometrial cancer. Clin Obstet Gynecol. 1978;5:675-94.
• Pflugfelder A, Kochs C, Blum A, et al. Malignant melanoma S3-guideline 'diagnosis, therapy and follow-up of melanoma.' J Dtsch Dermatol Ges 2013;11(suppl 6):1-126.